STOCK TITAN

nDatalyze (NDATF) Stock News

NDATF OTC
Rhea-AI Summary

nDatalyze (NDATF) named D’Arcy Funfer as president and CEO and appointed him to its board, with both appointments effective immediately. Funfer succeeds Gordon Crawford as a director, while outgoing president and CEO Jim Durward remains board chair.

The company has spent the past six months developing EpitomePD, its athletic assessment platform, and said it can now focus on commercialization, starting with hockey. The platform is designed to help amateur hockey players make more informed training decisions and can be used in other sports and high-performance markets.

nDatalyze granted 3,700,000 stock options to directors and officers under its stock option plan. The options have an exercise price of $0.05 per common share, expire two years from the grant date and are subject to a four-month hold period from that date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

nDatalyze (NDATF) has delivered notice terminating its proposed reverse takeover with Prism Diversified after the transaction missed its October 31, 2026 deadline. The parties did not agree to an extension. Escrowed subscription proceeds will be returned and subscription receipts cancelled because the financing’s release conditions were not met; no company shares will be issued under the financing.

The shareholder-approved spin-out and name change, both conditional on the takeover, will not proceed at this time. Shares remain halted, and nDatalyze plans to apply for trading reinstatement, subject to CSE review and approval. The company intends to continue commercializing its Epitome sports performance platform, whether privately or publicly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none